Tandem Diabetes Care Return on Equity (ROE) Growth & History (TNDM)
Tandem Diabetes Care's return on equity was −97.88% for fiscal 2025.
View full Tandem Diabetes Care company overviewTandem Diabetes Care annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −97.88% | −64.58 pp |
| 2024 | 2024-12-31 | −33.30% | +25.78 pp |
| 2023 | 2023-12-31 | −59.08% | −37.41 pp |
| 2022 | 2022-12-31 | −21.67% | −25.56 pp |
| 2021 | 2021-12-31 | 3.89% | +16.15 pp |
| 2020 | 2020-12-31 | −12.25% | +2.92 pp |
| 2019 | 2019-12-31 | −15.17% | +224.94 pp |
| 2018 | 2018-12-31 | −240.11% | — |
| 2016 | 2016-12-31 | −290.04% | −167.34 pp |
| 2015 | 2015-12-31 | −122.70% | −29.20 pp |
| 2014 | 2014-12-31 | −93.50% | +1237.85 pp |
| 2013 | 2013-12-31 | −1,331.34% | — |
Tandem Diabetes Care quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −16.11% | +20.21 pp |
| Q1 2026 | 2026-03-31 | −14.18% | +48.23 pp |
| Q4 2025 | 2025-12-31 | −0.41% | −0.71 pp |
| Q3 2025 | 2025-09-30 | −15.90% | −6.04 pp |
| Q2 2025 | 2025-06-30 | −36.32% | −23.39 pp |
| Q1 2025 | 2025-03-31 | −62.41% | −47.06 pp |
| Q4 2024 | 2024-12-31 | 0.30% | +9.86 pp |
| Q3 2024 | 2024-09-30 | −9.86% | +0.39 pp |
| Q2 2024 | 2024-06-30 | −12.92% | −2.21 pp |
| Q1 2024 | 2024-03-31 | −15.35% | +16.47 pp |
| Q4 2023 | 2023-12-31 | −9.56% | −5.88 pp |
| Q3 2023 | 2023-09-30 | −10.25% | +0.99 pp |
| Q2 2023 | 2023-06-30 | −10.71% | −7.32 pp |
| Q1 2023 | 2023-03-31 | −31.82% | −28.43 pp |
| Q4 2022 | 2022-12-31 | −3.68% | −6.31 pp |
| Q3 2022 | 2022-09-30 | −11.24% | −12.81 pp |
| Q2 2022 | 2022-06-30 | −3.39% | −4.61 pp |
| Q1 2022 | 2022-03-31 | −3.38% | −1.90 pp |
| Q4 2021 | 2021-12-31 | 2.63% | −2.28 pp |
| Q3 2021 | 2021-09-30 | 1.58% | +4.74 pp |
| Q2 2021 | 2021-06-30 | 1.22% | +12.63 pp |
| Q1 2021 | 2021-03-31 | −1.48% | +5.91 pp |
| Q4 2020 | 2020-12-31 | 4.91% | +3.44 pp |
| Q3 2020 | 2020-09-30 | −3.17% | −1.31 pp |
| Q2 2020 | 2020-06-30 | −11.42% | −10.28 pp |
| Q1 2020 | 2020-03-31 | −7.39% | +10.84 pp |
| Q4 2019 | 2019-12-31 | 1.47% | −1.52 pp |
| Q3 2019 | 2019-09-30 | −1.86% | +46.57 pp |
| Q2 2019 | 2019-06-30 | −1.14% | +312.51 pp |
| Q1 2019 | 2019-03-31 | −18.23% | — |
| Q4 2018 | 2018-12-31 | 2.99% | — |
| Q3 2018 | 2018-09-30 | −48.43% | — |
| Q2 2018 | 2018-06-30 | −313.65% | — |
| Q3 2016 | 2016-09-30 | −159.99% | −135.36 pp |
| Q2 2016 | 2016-06-30 | −46.98% | −26.42 pp |
| Q1 2016 | 2016-03-31 | −37.45% | −10.40 pp |
| Q4 2015 | 2015-12-31 | −17.96% | +12.30 pp |
| Q3 2015 | 2015-09-30 | −24.64% | +1.72 pp |
| Q2 2015 | 2015-06-30 | −20.56% | +0.67 pp |
| Q1 2015 | 2015-03-31 | −27.05% | −6.41 pp |
| Q4 2014 | 2014-12-31 | −30.26% | — |
| Q3 2014 | 2014-09-30 | −26.35% | — |
| Q2 2014 | 2014-06-30 | −21.23% | — |
| Q1 2014 | 2014-03-31 | −20.64% | — |
Tandem Diabetes Care return on equity trends
Over the last five fiscal years, Tandem Diabetes Care's return on equity decreased from −12.25% to −97.88%, a change of −85.63 percentage points. The latest reported quarter, Q2 2026, shows −16.11%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tandem Diabetes Care source filings ↗